# Phase I Study With V-212 Vaccinations in Healthy Adult Volunteers

> **NCT06975319** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Virometix** · enrollment: 60 (estimated)

## Conditions studied

- Healthy
- Immunisation Against Streptococcus Pneumoniae

## Interventions

- **BIOLOGICAL:** V-212 (or Placebo) administered by i.m injection (3 vaccinations) - low dose
- **BIOLOGICAL:** V-212 (or Placebo) administered by i.m injection (3 vaccinations) - medium dose
- **BIOLOGICAL:** V-212 (or Placebo) administered by i.m injection (3 vaccinations) - high dose

## Key facts

- **NCT ID:** NCT06975319
- **Lead sponsor:** Virometix
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-29
- **Primary completion:** 2025-12-02
- **Final completion:** 2026-07-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-08-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06975319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06975319, "Phase I Study With V-212 Vaccinations in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06975319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*